A Agilent Technologies Inc.

Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0

(NYSE: A) today announced the release of the AssayMAP Bravo Protein Sample Prep Workbench 4.0 software. This release adds 21 CFR Part 11 compliance-enabling features that allow AssayMAP Bravo-based automated sample preparation in workflows across the biopharma drug development process.

The requirement for labs to use instruments that comply with regulatory guidelines such as 21 CFR Part 11 or have the option of turning on compliance-enabling software features is moving to earlier stages of the drug development process. The AssayMAP Workbench 4.0 addresses these requirements and facilitates the seamless transfer of assays along the entire drug development process, including moving from non-compliant to compliant laboratories.

AssayMAP Workbench 4.0 simplifies the documentation required in regulated laboratories and desired in non-regulated labs by providing the option to generate reports that capture sample prep workflow data. The new AssayMAP software enables novice users to use the system with minimal training by providing a walk-up operation option.

“The addition of compliance enabling features, walk-up capabilities, and report generation provide our customers added value across the entire biopharma drug development process,” said Lars Kristiansen, general manager of Agilent’s Automation Solutions business. “These enhancements align with our focus to provide new solutions to our biopharma partners that enable them to bring biotherapeutics to market faster and more cost-effectively.”

AssayMAP Workbench 4.0 also expands software support for the recently released AssayMAP large-capacity cartridges. These cartridges enhance the ability of biopharma labs to analyze biotherapeutic critical quality attributes and enable more complete automation of sample prep workflows.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , , and .

EN
14/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch